Actively Recruiting
Safety and Tolerability Study of Single-Dose YKYY033 Injection in Healthy Adults with Randomized Placebo Control
Led by Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. · Updated on 2026-08-26
40
Participants Needed
1
Research Sites
33 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of a new drug called YKYY033 injection in healthy adult men and women aged 18 to 55 years. This is a Phase 1, randomized, double-blind, placebo-controlled study designed to carefully assess how the drug behaves in the body and its effects when given in increasing doses. The study is sponsored by Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. Participants will receive a single subcutaneous injection of either YKYY033 or a placebo in an ascending dose manner to monitor safety and drug behavior. The study includes parallel groups where participants are randomly assigned to receive the active drug or placebo. The dosing is a one-time injection, and the study observes participants for an extended period after administration. Throughout the study, participants will have various assessments including monitoring for adverse events, injection site reactions, and laboratory tests for pharmacokinetics and pharmacodynamics up to 337 days after the injection. Safety evaluations include electrocardiograms and coagulation factor measurements. Participants will be followed closely to track the drugs presence in the body and any side effects over nearly a year, ensuring thorough observation of safety and drug activity.
CONDITIONS
Brief Title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection
Research Team
Y
Yuting Zhou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here